Sonic Incytes Medical Corp.

Sonic Incytes Medical Corp. is a Canadian health technology company based in Vancouver, British Columbia, founded in 2017. The company focuses on developing portable, handheld medical imaging devices to assess liver health, particularly for chronic liver diseases like fatty liver disease. Its flagship product, Velacur™, is a point-of-care ultrasound device that provides real-time, 3D measurements of liver tissue stiffness and attenuation. This device offers diagnostic accuracy comparable to MRI elastography, making it a more accessible and affordable option for routine liver assessments. Sonic Incytes utilizes proprietary technology that combines ultrasound, elastography, artificial intelligence, and machine learning to deliver reliable insights into liver health. Sonic Incytes serves hospitals, clinics, specialized liver disease centers, and healthcare providers worldwide. The company aims to make liver health assessment routine and affordable, addressing the increasing global burden of chronic liver disease. With over $10 million in funding, Sonic Incytes is committed to advancing its technology and expanding its market presence.

• Employees 33
• Founded 2017
• Total Funding $10592866